Stay updated with breaking news from Ichnos Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology,...
Mumbai (Maharashtra) [India], May 31 (ANI/PRNewswire): EBITDA growth of 22.7 per cent to Rs 20,844 Mn with margins of 19 per cent. Consolidated Net Profit of Rs 9,701 Mn with growth of 25 per cent in FY21.
Share this article Share this article NEW YORK, May 21, 2021 /PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced that Alessandro Riva, M.D., will be leaving Ichnos effective August 15, 2021. We want to thank Dr. Riva for his visionary leadership as the first CEO of Ichnos. His strategic and scientific drive have given Ichnos a solid foundation to create and develop new medicines for patients. We wish him well in his future endeavors. Effective immediately, Cyril Konto, M.D., is ap...
Share this article Share this article NEW YORK, April 5, 2021 /PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today announced the appointment of Cyril Konto, M.D., to the new position of Chief Medical Officer (CMO), effective immediately. Dr. Konto, who reports to Chief Executive Officer Alessandro Riva, M.D., will oversee oncology clinical sciences, clinical operations, regulatory sciences, drug metabolism and pharmacokinetics, biometrics, drug safety, and quality. He will also work closely w...
Share this article Share this article NEW YORK, March 2, 2021 /PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today named Michael D. Price as Chief Financial Officer (CFO), effective immediately. Michael Price, formerly executive vice president and CFO at Akcea Therapeutics and a certified public accountant, is an experienced biotech financial professional, having served as a CFO of four such companies since 1992. At Akcea, recently acquired by Ionis Pharmaceuticals, he helped manage all aspec...